Cellestis GmbH

Stand no.  12

Cellestis GmbH - Cellestis – QuantiFERON®-TB Gold

Cellestis is focused on developing diagnostics tests that measure immune function for diseases with an unmet medical need.

Showcase content

As a modern alternative to the 110 year old Tuberculin Skin Test (TST), also known as the Mantoux, QFT offers unmatched specificity, high sensitivity and simplicity. QFT enables focused TB therapy by providing clinicians with an accurate, reliable and convenient TB diagnostic tool. QFT is unaffected by previous BCG vaccination and most other environmental mycobacteria. Unlike the TST, it requires only one patient visit, is a controlled laboratory test and provides an objective, reproducible result that is unaffected by subjective interpretation. Results can be available within 24 hours. More than 400 peer-reviewed scientific publications support the use of IGRAs such as the QFT.

Who are we targeting?

Chest Physicians, Occupational Health Physicians, Rheumatologists, TB Leads, TB Nurses, Consultant Communicable Disease Control (CCDC), Lab Managers (Microbiologists, Clinical Chemists), Biomedical Scientists (BMS)

Why NHS staff should visit our showcase?

QFT enables focused TB therapy by providing clinicians with an accurate, reliable and convenient TB diagnostic tool:

• Results available within 24 hours
• Only one patient visit required
• Objective, reproducible results
• Not affected by BCG vaccination
• Not subject to boosting

This provides the following benefits:

• Rapid, reliable results
• High cost effectiveness leading to overall cost savings
• Ability to increase testing compliance

QFT enables focused TB therapy by providing clinicians with an accurate, reliable and convenient TB diagnostic tool.

Contact:

events@cellestis.com

www.cellestis.com

Partners:

Cellestis is an industry partner of the AERAS Global TB Vaccine Foundation, FIND (the Foundation for Innovative New Diagnostics) and the Stop-TB Partnership.

QFT is sold directly in the U.S. by Cellestis Inc.; in Europe by Cellestis GmbH (Germany); and in Australia and Asia by Cellestis International Pty. Ltd. (Australia). QFT is also available through commercial partners in Japan, Europe, the Middle East and other countries worldwide.